Gilead Sciences
Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.
DitchCarbon Score
How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gilead Sciences's score of 58 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gilead Sciences's reported carbon emissions
In 2023, Gilead Sciences reported total greenhouse gas (GHG) emissions of approximately 1,179,798,000 kg CO2e. This figure includes 56,096,000 kg CO2e from Scope 1 (direct emissions), 22,339,000 kg CO2e from Scope 2 (indirect emissions from energy consumption), and a significant 1,121,798,000 kg CO2e from Scope 3 emissions, which encompass the entire value chain. Gilead has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 GHG emissions by 46% by 2030, using a 2019 baseline. Additionally, the company has pledged to cut its Scope 3 emissions by 15% over the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Furthermore, Gilead aims to achieve carbon net-zero operational GHG emissions by 2030, reinforcing its commitment to sustainability and environmental responsibility. The company’s strategy includes a near-term goal of reducing Scope 1 and 2 emissions by 25% by 2025 compared to a 2016 baseline. Overall, Gilead Sciences is actively working towards significant reductions in its carbon footprint, demonstrating a strong commitment to addressing climate change and promoting sustainable practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,813,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
